QQ客服 官方微博 反馈留言

	OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
	Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine; Armstrong, Anne
	2018
卷号	78期号:13
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2018-CT038
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6347121
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Robson, Mark E.,Im, Seock-Ah,Senkus, Elzbieta,et al. OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)[J],2018,78(13).
APA	Robson, Mark E..,Im, Seock-Ah.,Senkus, Elzbieta.,Xu, Binghe.,Domchek, Susan.,...&Conte, Pierfranco.(2018).OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).,78(13).
MLA	Robson, Mark E.,et al."OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)".78.13(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。